A Phase 2/3 interventional study of PRO 140 350 and PRO 140 525 in HIV-1-infection, sponsored by CytoDyn, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by CytoDyn, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a Phase 2b/3 multi-center extension study designed to evaluate the long term antiviral activity, safety, and tolerability of the strategy of continuing PRO 140 350mg, 525mg, or 700mg SC (subcutaneous) monotherapy to maintain viral suppression after initial 48 weeks in virologically suppressed subjects.
Consenting subjects will continue weekly PRO 140 350mg, 525mg, or 700mg monotherapy during the Treatment Extension Phase with the one-week overlap of existing retroviral regimen and PRO 140 350mg, 525mg, or 700 mg at the end of the treatment in subjects who do not experience virologic failure.
The objective is to assess the long-term safety of using PRO 140 350mg, 525mg, or 700mg SC as single-agent maintenance therapy for the chronic suppression of CCR5-tropic HIV-1 infection.
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of Bleeding Disorder or patients on anti-coagulant therapy (except aspirin).
Note: Subjects with well-controlled bleeding disorder while on stable anti-coagulant therapy dose with documented stable INRs can be enrolled as per discretion of the Investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRO 140 350mg weekly SC injection.
Drug: PRO 140 350
PRO 140 525mg weekly SC injection.
Drug: PRO 140 525
PRO 140 700mg weekly SC injection.
Drug: PRO 140 700
Pro140 SC injection 350 mg
Also known as: leronlimab
525 mg
Also known as: leronlimab
700 mg
Also known as: leronlimab
Long Term Clinical Safety of PRO 140 Monotherapy by Assessing the Number of Participants With Grade 2, 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale, and the Number of Participants With Treatment-emergent Serious Adverse Events.
The Division of AIDS (DAIDS) grading table provides an adverse event severity grading scale ranging from grades 1 to 5 with descriptions for each adverse event based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death (Note: This grade is not specifically listed on each page of the grading table). Treatment-Emergent Serious Adverse Events (TESAEs) are defined as serious adverse events with an onset on or after the first treatment.
Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Proportion of Participants Experiencing Virologic Failure for All Subjects Within Each Treatment Group.
Virological failure is defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group.
Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Time to Virologic Failure After Initiating PRO 140 Monotherapy for All Subjects Within Each Treatment Group.
Virological failure (VF) is defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group. The date of VF event is defined as the date of the second assessment of the two (2) consecutive HIV-1 RNA levels of \>= 200 copies/mL when virological failure is confirmed. Subjects who did not have VF, the last visit date will be used as the date of the event.
Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Proportion of Participants Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.
Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group.
Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Time to Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group.
Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group.
Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Proportion of Virologic Failure Subjects Achieving Viral Re-suppression With Re-initiation of Previous Baseline Antiretroviral Regimen Within Each Treatment Group.
Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group. Subjects who experienced virologic failure during the treatment phase had an option to re-initiate their PRO 140 regimen to their previous baseline or dose escalate to the next dose level.
Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase for All Subjects Within Each Treatment Group
The change from baseline in CD4 cell count was summarized for each visit during the treatment phase for each treatment group. The time-weighted mean of change of the post baseline (visit TE1) values was calculated. The time-weighted mean was adjusted AUC (area under the curve) by time.
Time frame: From TE1 (first treatment administration) to last treatment visit, up to 197 weeks
| Milestone | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| Started | 8 | 18 | 30 |
| Completed | 0 | 2 | 1 |
| Not completed | 8 | 16 | 29 |
| Withdrew: Study early termination | 8 | 16 | 29 |
The Division of AIDS (DAIDS) grading table provides an adverse event severity grading scale ranging from grades 1 to 5 with descriptions for each adverse event based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death (Note: This grade is not specifically listed on each page of the grading table). Treatment-Emergent Serious Adverse Events (TESAEs) are defined as serious adverse events with an onset on or after the first treatment.
| participants | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| Participants with Grade 2, 3, or 4 AEs | 5 | 6 | 6 |
| Participants with TESAEs | 3 | 5 | 2 |
Virological failure is defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group.
| proportion of participants | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| Proportion of Participants Experiencing Virologic Failure for All Subjects Within Each Treatment Group. | 0 | 0.17 | 0.37 |
Virological failure (VF) is defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group. The date of VF event is defined as the date of the second assessment of the two (2) consecutive HIV-1 RNA levels of \>= 200 copies/mL when virological failure is confirmed. Subjects who did not have VF, the last visit date will be used as the date of the event.
| days | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| Time to Virologic Failure After Initiating PRO 140 Monotherapy for All Subjects Within Each Treatment Group. | 1148.88 ± 457.15 | 735.67 ± 326.71 | 582.00 ± 407.71 |
Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group.
| Portion of Participants | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| Proportion of Participants Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group. | — | 1 | 0.9 |
Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group.
| days | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| Time to Achieving Viral Re-suppression After Experiencing Virologic Failure Within Each Treatment Group. | — | 100.33 ± 33.48 | 136.71 ± 127.68 |
Viral re-suppression is defined as having HIV-1 RNA levels of \< 50 copies/mL after experiencing virologic failure within each treatment group. Subjects who experienced virologic failure during the treatment phase had an option to re-initiate their PRO 140 regimen to their previous baseline or dose escalate to the next dose level.
| proportion of participants | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| Proportion of Virologic Failure Subjects Achieving Viral Re-suppression With Re-initiation of Previous Baseline Antiretroviral Regimen Within Each Treatment Group. | — | 0.33 | 0.78 |
The change from baseline in CD4 cell count was summarized for each visit during the treatment phase for each treatment group. The time-weighted mean of change of the post baseline (visit TE1) values was calculated. The time-weighted mean was adjusted AUC (area under the curve) by time.
| cells/uL | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase for All Subjects Within Each Treatment Group | 0.62 ± 2.60 | -0.14 ± 2.59 | 0.58 ± 2.32 |
Collected over Report initiation for all adverse events began at the time of the first treatment extension visit and continued up until the final study visit (up to approximately 197 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PRO 140 350 mg | 1/8 (12.5%) | 3/8 (37.5%) | 6/8 (75%) |
| PRO 140 525 mg | 1/18 (5.6%) | 5/18 (27.8%) | 9/18 (50%) |
| PRO 140 700 mg | 0/30 (0%) | 2/30 (6.7%) | 18/30 (60%) |
| Event | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| Atrioventricular block completeCardiac disorders | 1/8 | 0/18 | 0/30 |
| Lacunar infarctionNervous system disorders | 1/8 | 0/18 | 0/30 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/8 | 0/18 | 0/30 |
| OverdoseInjury, poisoning and procedural complications | 1/8 | 0/18 | 0/30 |
| Pancreatitis acuteGastrointestinal disorders | 0/8 | 2/18 | 0/30 |
| COVID-19Infections and infestations | 0/8 | 1/18 | 0/30 |
| COVID-19 pneumoniaInfections and infestations | 0/8 | 1/18 | 0/30 |
| PancreatitisGastrointestinal disorders | 0/8 | 1/18 | 0/30 |
| Pancreatitis necrotisingGastrointestinal disorders | 0/8 | 1/18 | 0/30 |
| Sleep Apnoea SyndromeRespiratory, thoracic and mediastinal disorders | 0/8 | 1/18 | 0/30 |
| Event | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/8 | 2/18 | 1/30 |
| NasopharyngitisInfections and infestations | 3/8 | 3/18 | 1/30 |
| Seasonal allergyImmune system disorders | 3/8 | 1/18 | 0/30 |
| Actinic keratosisSkin and subcutaneous tissue disorders | 2/8 | 0/18 | 0/30 |
| Back painMusculoskeletal and connective tissue disorders | 2/8 | 1/18 | 1/30 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/8 | 0/18 | 0/30 |
| Dental cariesGastrointestinal disorders | 2/8 | 1/18 | 0/30 |
| DysuriaRenal and urinary disorders | 2/8 | 0/18 | 0/30 |
| FatigueGeneral disorders | 2/8 | 1/18 | 1/30 |
| HypertensionVascular disorders | 2/8 | 0/18 | 0/30 |
All patients who received at least one dose of PRO 140 (leronlimab) were included in the baseline analysis population. Study was early terminated.
| Age, Categorical(Participants) | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 17 | 28 | 52 |
| >=65 years | 1 | 1 | 2 | 4 |
| Age, Continuous(years) | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg | Total |
|---|---|---|---|---|
| Mean | 59.88 ± 8.37 | 47.17 ± 11.94 | 47.77 ± 13.10 | 49.30 ± 12.90 |
| Sex: Female, Male(Participants) | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg | Total |
|---|---|---|---|---|
| Female | 1 | 3 | 0 | 4 |
| Male | 7 | 15 | 30 | 52 |
| Ethnicity (NIH/OMB)(Participants) | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 5 | 9 |
| Not Hispanic or Latino | 8 | 14 | 25 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 4 | 7 |
| White | 7 | 13 | 26 | 46 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | PRO 140 350 mg | PRO 140 525 mg | PRO 140 700 mg | Total |
|---|---|---|---|---|
| United States | 8 | 18 | 30 | 56 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Jun 2022, 57 months.
Results were first posted in Oct 2025, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab